Chronic Tendinopathy: A New Neurobiological Perspective on Pain and Healing

Introduction

Tendinopathy, once regarded mainly as a degenerative or overload injury of tendon collagen, is now recognized as a much more complex neurobiological condition. Traditional models emphasized mechanical stress and microtrauma, describing tendon pain as an imbalance between damage and repair. However, recent research has revealed that nerve ingrowth (neoinnervation) and neuroinflammatory signaling within the paratenon—the thin, vascularized sheath surrounding the tendon—play a central role in driving chronic tendon pain.

Neoinnervation and the Paratenon

The paratenon facilitates tendon gliding and nutrient exchange but also serves as a key site of nociceptive activity. In chronic tendinopathy, excessive and prolonged nerve sprouting from the paratenon into the tendon proper has been repeatedly documented. These new sensory nerve fibers release neurochemicals such as substance P, glutamate, and calcitonin gene-related peptide (CGRP)—potent mediators of pain and inflammation.

This phenomenon, termed neoinnervation, transforms the tendon from a largely aneural structure into a pain-sensitive one. The result is a cycle of nerve growth, neuroinflammation, and impaired healing. These findings mark a major shift in understanding tendon pathology—not simply as degeneration, but as a disorder of neural dysregulation.

Scope and Methods of Review

A recent scoping review (Pain Physician, 2025) systematically analyzed 26 studies published between 2001 and 2022. The review included 21 human and 5 animal studies examining neural biomarkers, paratenon function, and nerve sprouting in chronic tendinopathy. Most human studies used immunohistochemistry and fluorescence microscopy on living tendon biopsies, while animal models investigated nerve and healing responses following experimentally induced tendon injuries.

Key Findings

• Prevalence of Neoinnervation:
  73% of studies confirmed nerve ingrowth in chronic tendinopathy, often coexisting with angiogenesis (new blood vessel formation).
• Role of the Paratenon:
  77% of studies identified the paratenon as a major site of nociceptive and regenerative signaling. Neural markers like NMDAR1, substance P, and PGP 9.5 were consistently expressed here.
• Neural Biomarkers Upregulated:
  • PGP 9.5: Found in 15 studies — general nerve marker.
  • Substance P: 13 studies — pain and inflammation mediator.
  • CGRP: 9 studies — contributes to vasodilation and pain sensitivity.
  • Tyrosine hydroxylase, neuropeptide Y, and GAP-43: markers of sympathetic activity and nerve regeneration.
  • NMDAR1 and NK1R receptors: indicate glutamatergic and substance P pathways are active in chronic pain.

These markers underscore that tendon pain is mediated by both sensory and autonomic nerve changes, interacting with immune cells such as macrophages, mast cells, and T-cells. The presence of chemokines (CCL2, CXCL10) further supports a neuro-immune feedback loop in chronic tendinopathy.

Research Trends

Over the past two decades, biomarker research has evolved from merely identifying nerve fibers to mapping complex neurogenic–immune interactions. Early studies focused on general markers like PGP 9.5, while more recent work explores neurotransmitter receptors and inflammatory mediators. This reflects a broader understanding of tendon pain as a multi-system disorder involving neural, vascular, and immune systems.

Clinical Implications

The neurobiological model of tendinopathy suggests that therapies targeting neoinnervation and the paratenon may improve outcomes beyond traditional mechanical approaches.

Emerging treatments—such as ultrasound-guided tenotomy (PUT, TENEX®), radiofrequency modulation, and focused manual therapies—may alleviate pain by disrupting abnormal nerve growth or modulating neuroinflammatory pathways. Meanwhile, neuropeptide-based therapies (e.g., targeting the substance P–NK1R axis) hold promise for pharmacological pain modulation.

For therapists, this means reassessing chronic tendon pain not as a simple tissue failure but as a neurogenic and immune-driven condition, requiring interventions that address both mechanical loading and neurosensory regulation.

Future Directions

The review highlights the need for:

• Longitudinal studies to track how nerve ingrowth evolves with time and treatment.
• Clinical trials testing therapies that modulate paratenon or neural signaling.
• Integration of biomarker profiling to personalize rehabilitation protocols.

A clearer understanding of the neuro-immune interface could ultimately transform tendinopathy management from symptomatic relief to true neurosomatic healing.

---

Key Takeaway:
Chronic tendinopathy is not merely a degenerative lesion—it is a neurobiological disorder driven by aberrant nerve growth and neuroinflammation within the paratenon. Therapies that combine biomechanical loading with neural modulation represent the next frontier in tendon rehabilitation.

Wahezi, Sayed Emal. “Chronic Tendinopathy Driven by Neoinnervation: The Role of the Paratenon, Upregulated Neural Biomarkers, and Evolving Evidence–A Scoping.” Pain Physician 28 (2025): 287-297.